Abnormal increases of antiphospholipid antibody and plasma homocysteine levels are recently emerging as nonlipidic risk factors for cerebral atherogenesis and thrombosis. Both antiphospholipid antibody and homocysteine share many similar bioeffects in hemostasis, but their interaction is still inconsistent. In this study, we examined the relation between the plasma homocysteine level and lupus anticoagulant, anticardiolipin antibody, and anti-β2-glycoprotein I antibody in patients with noncardiac cerebral ischemia. Systemic lupus erythrematosus patients were excluded. The results showed a higher frequency of moderate hyperhomocysteinemia in patients with an abnormal increase of lupus anticoagulant only. Neither the serum folate and cobalamin levels nor methylenetetrahydrofolate reductase allele mutation contributes to this result. Accordingly, homocysteine interacts with lupus anticoagulant to promote cerebral atherosclerosis and ischemia. The role of vasculopathic or prothrombotic autoantibody generation in response to specific pathological change such as hyperhomocysteinemia warrants further investigation.
Tuhrim S.Antiphospholipid antibodies and stroke. Curr Cardiol Rep. 2004;6:130-134.
2.
Asherson RA, Khamashta MA, Gil A., et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med.1989;86:391-399.
3.
Bots ML, Launer LJ, Lindemans J., et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med.1999; 159:38-44.
4.
McQuillan BM , Beilby JP, Nidorf M., Thompson PL, Hung J.Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening: the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation. 1999;99:2383-2388.
5.
Adachi H., Hirai Y., Fujiura Y., Matsuoka H., Satoh A., Imaizumi T.Plasma homocysteine levels and atherosclerosis in Japan: epidemiological study by use of carotid ultrasonography. Stroke. 2002;33:2177-2181.
6.
Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SBHomocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies . Int J Epidemiol.2002;31:59-70.
7.
de Groot PG, Derksen RHAntiphospholipid antibodies: update on detection, pathophysiology, and treatment . Curr Opin Hematol.2004;11:165-169.
8.
Angles-Cano E., Guillin MCAntiphospholipid antibodies and the coagulation cascade. Rheum Dis Clin North Am.2001;27:573-586.
9.
Undas A., Brozek J., Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost.2005;94:907-915.
10.
Ebbesen LSHyperhomocysteinemia, thrombosis and vascular biology. Cell Mol Biol. 2004;50:917-930.
11.
Avivi I., Lanir N., Hoffman R., Brenner B.Hyperhomocysteinemia is common in patients with antiphospholipid syndrome and may contribute to expression of major thrombotic events. Blood Coagul Fibrinolysis. 2002;13:169-172.
12.
Chen WH, Lan MY, Chang YY, Chen SS, Liu JSThe prevalence of protein C, protein S, and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral ischemia. Clin Appl Thromb Hemost. 2003;9:155-162.
13.
Chen WHAnti-beta2-glycoprotein I antibody and hypertension in cerebral ischemia. Clin Appl Thromb Hemost. 2004;10:55-60.
14.
Chen WH, Kao YF, Lan MY, Chang YY, Chen SS, Liu JSThe increase of blood anticardiolipin antibody depends on the underlying etiology in cerebral ischemia. Clin Appl Thromb Hemost. 2005;11:203-210.
15.
Stabler SP, Marcell PD, Podell ER, Allen RHQuantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem.1987;162:185-196.
16.
Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet.1995;10:111-113.
17.
Simmelink MJ , Horbach DA, Derksen RH, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol.2001;113:621-629.
18.
Pengo V., Brocco T., Biasiolo A., Rampazzo P., Carraro P., Zamarchi R.Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood. 1999; 94:3814-3819.
19.
Takeya H., Mori T., Gabazza EC, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids . J Clin Invest.1997;99:2260-2268.
20.
Gallart T., Benito C., Reverter JC, et al. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol.2002;116:875-886.
21.
Pengo V., Biasiolo A., Rampazzo P., Brocco T.dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost.1999;81:256-258.
22.
Lopez FF, Sweeney JD, Blair AJ, Sikov WMSpontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant. Am J Hematol.1999 ;62:58-60.
23.
Seriolo B., Fasciolo D., Sulli A., Cutolo M.Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol.2001;19:561-564.
24.
Ames PR, Margaglione M., Tommasino C., Bossone A., Iannccone L., Brancaccio V.Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2001;12:699-704.
25.
Fijnheer R. , Roest M., Haas FJ, De Groot PG, Derksen RHHomocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol.1998;25:1737-1742.
26.
Frijns CJ, Derksen RH, De Groot PG, Algra A., Fijnheer R.Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol.2001;125:149-154.
27.
Chen WH, Kao YF, Lan MY, Chang YY, Liu JSA perturbation of antithrombin-III and protein C coupling associates with an increase of anti-beta2-glycoprotein I antibody in non-antiphospholipid antibody syndrome cerebral ischemia. Blood Coagul Fibrinolysis . 2002;13:703-709.
28.
Bhattacharya M., Biswas A., Kannan M., et al. Clinicohematologic spectrum in patients with lupus anticoagulant. Clin Appl Thromb Hemost. 2005;11:191-195.
29.
Tuhrim S., Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity . Stroke. 1999;30:1561-1565.
30.
Vaarala O., Manttari M., Manninen V., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
31.
Cappucci G. , Margaglione M., Ames PRComparative prevalence of antiphospholipid antibodies and thrombophilic genotypes in consecutive patients with venous thrombosis. Blood Coagul Fibrinolysis.2001 ;12:659-665.
Jakubowski H.Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J.1999;13:2277-2283.
34.
Jakubowski H.Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med.2005;43:1011-1014.
35.
Ferguson E. , Parthasarathy S., Joseph J., Kalyanaraman B.Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low-density lipoprotein. J Lipid Res.1998 ;39: 925-933.
